Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 118
Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
Research Type Human Reported as Clinical Trial Date March 09, 2018 Authors Mitchell R. K. L. Lie, Janine van der Giessen, Gwenny M. Fuhler, Alison de Lima, Maikel P. Peppelenbosch, Cokkie van der Ent and C. Janneke van der Woude Institution Erasmus University Medical Center Rotterdam Disease Crohn's Disease, IBD, Ulcerative Colitis
BACKGROUND: Around 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or relapse over time. Novel treatments are called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible alternative treatment option for these patients. We investigated the potential of LDN to induce clinical response in therapy refractory IBD patients, and investigated its direct effects on epithelial barrier function. METHODS: Patients not in remission and not resp...
The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders.
Research Type Human Reported as Review Date January 27, 2018 Authors Denise K. Patten, Bob G. Schultz, Daniel J Berlau Institution Regis University School of Pharmacy Disease Crohn's Disease, Fibromyalgia, MS (Multiple Sclerosis), Pain (chronic)
Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off-label, complimentary, or alternative medicines to gain relief from symptoms. Low-dose naltrexone has been used off-label for treatment of pain and inflammation in multiple sclerosis, Crohn's disease, fibromyalgia, and other diseases. Naltrexone is a mu-opioid receptor antagonist indic...
The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 27, 2018 Authors Guttorm Raknes, Pia Simonsen, Lars Småbrekke Institution University Hospital of North Norway Disease Crohn's Disease, IBD, Ulcerative Colitis
BACKGROUND AND AIMS: Low dose naltrexone (LDN) is a controversial off-label treatment used by many Crohn’s disease (CD) and ulcerative colitis (UC) patients. A small number of preliminary studies indicate that LDN might be beneficial in CD, but evidence is too scarce to demonstrate efficacy. We wanted to examine whether initiation of LDN therapy by patients with inflammatory bowel disease (IBD) was followed by changes in dispensing of relevant medication. METHODS: We performed a quasi-experim...
Variable Response to Naltrexone in Patients With Hailey-Hailey Disease
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 17, 2018 Authors Severine Cao; Evelyn Lilly; Steven T. Chen Institution Harvard Medical School; Massachusetts General Hospital Disease Hailey-Hailey
Hailey-Hailey disease (HHD) is a genetic intraepidermal blistering disorder characterized by chronic macerated erosions in intertriginous areas. The recent report of 2 case series demonstrating the efficacy of low-dose naltrexone in the treatment of HHD represents exciting progress in the management of a disease with limited therapeutic options. Herein we present 3 additional cases of HHD demonstrating varying responses to naltrexone. ...
Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 11, 2018 Authors Leonard B Weinstock, Jill B Brook,Trisha L Myers, Brent Goodman Institution Washington University, Specialists in Gastroenterology, Mayo Clinic Arizona Disease MCAS (mast cell activation syndrome), POTS (postural orthostatic tachycardia)
A patient with severe postural orthostatic tachycardia syndrome (POTS ) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN), intravenous immunoglobulin (IVIg), and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCA...
Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis
Research Type Human Date January 01, 2018 Authors Ludwig MD, Zagon IS, McLaughlin PJ Institution Pennsylvania State University Disease MS (Multiple Sclerosis)
ABSTRACT: The endogenous neuropeptide opioid growth factor, chemically termed [Met5]-enkephalin, has growth inhibitory and immunomodulatory properties. Opioid growth factor is distributed widely throughout most tissues, is autocrine and paracrine produced, and interacts at the nuclear-associated receptor, OGFr. Serum levels of opioid growth factor are decreased in patients with multiple sclerosis and in animals with experimental autoimmune encephalomyelitis suggesting that the OGF-OGFr p...
The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol.
Research Type Human Reported as Case Report/Series/Restrospective Study Date December 01, 2017 Authors Berkson BM, Calvo-Riera F Institution Oklahoma State University, The Integrative Medical Center of New Mexico, Clinic for Autoimmune and Chronic Diseases (Spain) Disease Cancer (general), Renal Cell Carcinoma
In this case report, we describe the treatment of a 64-year-old male patient diagnosed with metastatic renal cell carcinoma (RCC) in June of 2008. In spite of a left nephrectomy and the standard oncological protocols, the patient developed a solitary left lung metastasis that continued to grow. He was informed that given his diagnosis and poor response to conventional therapy, any further treatment would, at best, be palliative. The patient arrived at the Integrative Medical Center of New...
Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris
Research Type Human Reported as Case Report/Series/Restrospective Study Date November 16, 2017 Authors Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Institution New York University Disease Lichen Planopilaris
Lichen planopilaris (LPP) is a variant of lichen planus that affects the scalp causing scarring hair loss. Patients also frequently experience symptoms of scalp itch, pain, and burning. To date, there are no long-term remittive nor curative therapies available. Low-dose naltrexone has anti-inflammatory properties and has recently been described in the context of treating autoimmune conditions. This retrospective medical record review describes four LPP patients treated with low-dose (3 mil...
Psychoneuroimmunological approach to gastrointestinal related pain
Research Type Human Reported as Case Report/Series/Restrospective Study Date November 06, 2017 Authors Toljan K, Vrooman B Institution University of Zagreb School of Medicine Dartmouth-Hitchcock Medical Center Disease IBD, Pain (chronic)
BACKGROUND AND PURPOSE (AIMS):Psychoneuroimmunology is both a theoretical and practical field of medicine in which human biology and psychology are considered an interconnected unity. Through such a framework it is possible to elucidate complex syndromes in gastrointestinal related pain, particularly chronic non-malignant. The aim is to provide insight into pathophysiological mechanisms and suggest treatment modalities according to a comprehensive paradigm. The article also presents novel findin...
Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study
Research Type Human Reported as Case Report/Series/Restrospective Study Date November 03, 2017 Authors Raknes G, Småbrekke, L Institution University Hospital of North Norway Disease MS (Multiple Sclerosis)
Low dose naltrexone (LDN) has become a popular off-label therapy for multiple sclerosis (MS). A few small, randomized studies indicate that LDN may have beneficial effects in MS and other autoimmune diseases. If proven efficacious, it would be a cheap and safe alternative to the expensive treatments currently recommended for MS. We investigated whether a sudden increase in LDN use in Norway in 2013 was followed by changes in dispensing of other medications used to treat MS. We performed a quasi-...